Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

Protein aggregation — pathways and influencing factors

Wang W, Nema S, Teagarden D. International Journal of Pharmaceutics 2010

Document identifier
CEI-BR-118
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
Wang W, Nema S, Teagarden D
Title
Protein aggregation — pathways and influencing factors
Source
International Journal of Pharmaceutics
Year
2010
Volume, issue, pages
390(2):89–99
Digital object identifier
10.1016/j.ijpharm.2010.02.025
PubMed identifier
20188795
Record type
Journal article
Institute identifier
CEI-BR-118

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

DocumentSeries
Monograph: CagrilintideCompound monograph
Monograph: PetrelintideCompound monograph
Monograph: IGF-1 LR3Compound monograph
Monograph: LL-37Compound monograph
Monograph: GlutathioneCompound monograph
Standard CEI-MS-07: Sub-visible particulate matter in reconstituted peptide solutionsMethodological standard
Standard CEI-MS-11: Determination of aggregate content by size-exclusion chromatographyMethodological standard
Standard CEI-MS-09: Assessment of appearance, cake integrity and reconstitution behaviourMethodological standard
Standard CEI-MS-21: Freeze–thaw and in-use stability assessment of reconstituted peptide…Methodological standard
Synthesis: Reconstitution practice and delivered doseEvidence synthesis
Synthesis: In-use stability of reconstituted peptide solutionsEvidence synthesis
Synthesis: Petrelintide in obesity and overweight in adults: effect on the…Evidence synthesis
Synthesis: Petrelintide in obesity and overweight in adults: tolerability and…Evidence synthesis
13 citing documents.

§1.3Subject tags

aggregation stability formulation

Compound Evidence Institute · CEI-BR-118 · https://compoundevidence.com/bibliography/wang2010/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.